about
Nanomedicine concepts in the general medical curriculum: initiating a discussionBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesLocoregional drug delivery using image-guided intra-arterial drug eluting bead therapyPolymeric nanoparticles for targeted treatment in oncology: current insightsConvergence of nanotechnology and cancer prevention: are we there yet?Nanotechnologies for noninvasive measurement of drug releaseUltrastructural interactions and genotoxicity assay of cerium dioxide nanoparticles on mouse oocytesPhotoacoustic imaging of tumor targeting with riboflavin-functionalized theranostic nanocarriers.Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.The Theranostic Path to Personalized NanomedicineNovel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer.Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imagingOsteosarcoma Overview.Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo.Cancer targeted therapeutics: From molecules to drug delivery vehicles.Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapyA cyclic-RGD-BioShuttle functionalized with TMZ by DARinv "Click Chemistry" targeted to αvβ3 integrin for therapy.Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablationGuided Delivery of Polymer Therapeutics Using Plasmonic Photothermal Therapy.BioShuttle mobility in living cells studied with high-resolution FCS & CLSM methodologiesMolecular mechanism of a novel CD59-binding peptide sp22 induced tumor cells apoptosis.Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumorsMedical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acidPolylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents.Cancer cell invasion: treatment and monitoring opportunities in nanomedicine.On the mechanism of targeting of phage fusion protein-modified nanocarriers: only the binding peptide sequence mattersProteomic analysis of early response lymph node proteins in mice treated with titanium dioxide nanoparticlesA polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapyUtilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer.Fluorophore labeling of core-crosslinked polymeric micelles for multimodal in vivo and ex vivo optical imaging.External beam radiotherapy synergizes ¹⁸⁸Re-liposome against human esophageal cancer xenograft and modulates ¹⁸⁸Re-liposome pharmacokinetics.Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacyVirosomes of hepatitis B virus envelope L proteins containing doxorubicin: synergistic enhancement of human liver-specific antitumor growth activity by radiotherapy.Comparative effect of gold nanorods and nanocages for prostate tumor hyperthermia.Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors.Targeted delivery of nanomedicines.Dual-functional c(RGDyK)-decorated Pluronic micelles designed for antiangiogenesis and the treatment of drug-resistant tumor.Investigating the specific uptake of EGF-conjugated nanoparticles in lung cancer cells using fluorescence imaging.Biological rationale for the design of polymeric anti-cancer nanomedicines.
P2860
Q26775137-92F32660-8325-4EC6-9858-83B37D5CFFC2Q26783705-5532305B-106E-4BD8-BC5A-193173CE22A9Q27015918-548175C5-20DD-4DCC-BECC-723D0F822644Q28087243-13E35409-6559-4558-91EE-744191B95832Q28386699-9FBA3643-595F-4D3F-B89B-6FB285155EFAQ28387499-3C587384-18F6-4365-B3A3-3B37BB7F629FQ28392557-AACED8F3-AFDD-4A29-B193-25E2D0B04EB9Q30355156-47FA4E30-B9CB-482D-9993-39CF73D51E9BQ30366990-814BA22B-23FE-4F7A-9622-C7AF1243383FQ30437998-C2CF49FA-80CE-4F0C-851B-50671E779EA8Q30997567-AB315B17-CB02-4D2B-A2D3-1DCEE765CD9BQ33651804-4764A661-0E9E-4B05-BFAE-F9FC9FE87FC0Q33725511-B179BBF2-1998-4165-86A0-F62B006D20DEQ33809324-17111B34-5B1E-412E-9CA2-BE1AC243EEA4Q33874414-19B55FF1-BEDE-4188-8EF1-61AE7AC5A986Q33887986-48F134A8-9E4E-4702-80DC-7F350EE94AC3Q34089324-5AE0F165-D912-40B4-B84E-78839CA8ACC6Q34167014-C0C3A667-1D1A-4D4D-831B-631D441C2CFAQ34217254-FB6C964D-3577-4FA5-8E6B-DCE321150BB2Q34318312-CFD36713-E110-4F72-B7E8-9EC07C6106EEQ34343478-F8E5EF59-2D4A-4DDD-813A-4413C160E415Q34347455-8D7A28E1-C41F-4F71-A3E9-3B9425AC23DCQ34647228-4C29E6A9-3EF7-45CE-BE20-74A987783084Q34786475-50F37810-B8DC-416F-A4CB-DC85A7EF3611Q35071594-7C3C8F25-37EA-4EDB-9664-40D05CD00125Q35093966-7120680A-5CF3-4577-9EA8-083E07B3260DQ35256650-657B51AA-AFA4-46AF-BDBB-337D00766A23Q35549102-18531CC1-3585-4AB2-A368-43906A0B7B89Q35556939-5D84BAE7-813A-4B30-A055-7349FCF4CBC0Q35578037-463BEE23-D027-40B9-8A66-4843D37F15B4Q35619572-25F15A9A-1C04-4893-80C2-401085DE7468Q35659165-B88CFDF3-03C2-4124-970D-41267E5B6922Q35679856-EA4C0212-2F89-456A-A55F-441226A5A91DQ35804205-9403D611-B520-46C3-8427-96ACBA2D11CAQ35829879-C5C1841F-DBC9-4CE6-BFEC-A3FC66FD52FFQ35901007-0C1FE832-FB11-44C7-AEE8-6DF46972B6B1Q35915020-5859FBFF-1281-49E5-9EDF-0115F934C36AQ35918831-3827DB23-9659-45D7-9EA6-79B0070DA4B6Q35979595-35EDF091-2F08-4F08-B33B-4D29D0AD713CQ36160333-60E807CA-314F-4B9F-BDC8-ECDC1B2F092C
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Tumour-targeted nanomedicines: principles and practice.
@en
type
label
Tumour-targeted nanomedicines: principles and practice.
@en
prefLabel
Tumour-targeted nanomedicines: principles and practice.
@en
P2860
P356
P1476
Tumour-targeted nanomedicines: principles and practice
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604483
P407
P50
P577
2008-07-22T00:00:00Z